Search - tctmd.com

Displaying 81 - 100 of 223

Sort: Relevancy | Date

Presentation TCT 2019

Welcome and Introductions

Presenter: Roxana Mehran

September 26, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Shelley Wood

September 19, 2019

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Todd Neale

September 24, 2018

Presentation TCT 2018

EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent

Presenter: Dominick J. Angiolillo, Neal S. Kleiman, Ajay J. Kirtane

September 24, 2018

Presentation TCT 2018

Switching Dual Antiplatelet Therapy After PCI: Who, When, Why, and How?

Presenter: John A. Bittl, C. Michael Gibson, Matthew J. Price

September 23, 2018

News Daily News TCT 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

Michael O'Riordan

September 23, 2018

Presentation TCT 2018

Benefits of Pretreatment With Dual Antiplatelet Therapy Prior to PCI in Stable CAD and ACS: Myth or Reality?

Presenter: John A. Bittl, C. Michael Gibson, Giuseppe Tarantini

September 23, 2018

Polymer-Free BioFreedom Stent as Safe as Orsiro, but Not as Effective

News Conference News TCT 2018

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

Michael O'Riordan

September 22, 2018

News Conference News TCT 2018

ReCre8: Physician-Led Study Shows Noninferiority of Polymer-Free Stent Compared With Permanent-Polymer ZES at 1 Year

Yael L. Maxwell

September 22, 2018

Presentation TCT 2018

LEADERS FREE II: Evaluation of a Polymer-Free Coronary Drug-Eluting Stent in High Bleeding-Risk Patients With One-Month Dual Antiplatelet Therapy

Presenter: Mitchell W. Krucoff

September 22, 2018

News Conference News TCT 2018

The End of BMS? LEADERS FREE II Shows Superiority of Polymer-Free, Drug-Coated Stent

Yael L. Maxwell

September 22, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day One: ‘Back to the Future’ With Stents, Stents, and More Stents

Shelley Wood

September 22, 2018

Advertisement

Welcome and Introductions

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent

Switching Dual Antiplatelet Therapy After PCI: Who, When, Why, and How?

High Mortality but Durable Results With Valve-in-Valve TAVR

Benefits of Pretreatment With Dual Antiplatelet Therapy Prior to PCI in Stable CAD and ACS: Myth or Reality?

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

ReCre8: Physician-Led Study Shows Noninferiority of Polymer-Free Stent Compared With Permanent-Polymer ZES at 1 Year

LEADERS FREE II: Evaluation of a Polymer-Free Coronary Drug-Eluting Stent in High Bleeding-Risk Patients With One-Month Dual Antiplatelet Therapy

The End of BMS? LEADERS FREE II Shows Superiority of Polymer-Free, Drug-Coated Stent

TCT 2018, Day One: ‘Back to the Future’ With Stents, Stents, and More Stents

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content